CLOs on the Move

Leafline Labs

www.leaflinelabs.com

 
LeafLine Labs was founded by practicing physicians who see the unnecessary suffering patients endure every day. We are, first and foremost, caregivers who exist to give our patients the quality of life they deserve.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Processo Partners, In

Processo Partners, In is a Miami, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Intellect Neurosciences

Intellect Neurosciences Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Symphogen

Symphogen, Inc. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Harvard MedTech

Harvard Medtech`s mission is to solve pain and related afflictions by providing unmatched Tele-PainCare™ solutions that promote safe, effective healing holistically and organically in conjunction with, or preferably in lieu of, surgery and prescription pain medications. Our Vx Pain Relief Program uniquely integrates state-of-the-art Virtual Reality Therapy with Behavioral Health Clinicians, who regularly provide psychological and social interventions by telephone to patients in the comfort of their homes while keeping the prescribing physician apprised of the patient`s progress. Our FDA-registered, clinically validated, whole-person approach to delivering safe, effective, at-home care yields more complete, convenient, timely and affordable relief of pain, depression, anxiety and related afflictions while requiring zero investment by the prescribing physician.

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.